US-based biopharmaceutical company Realm Therapeutics has submitted its first investigational new drug (IND) application for PR022 to the US Food and Drug Administration (FDA) for the treatment of patients affected with atopic dermatitis (AD).

PR022 is a non-alcohol based topical gel, in which the active moiety is a patented high concentration of hypochlorous acid that provides a differentiated mechanism of action for the treatment of a significant disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Once accepted by the US FDA, the IND application will allow the bio-pharmaceutical company to commence a Phase IIa proof-of-concept trial for patients suffering from AD.

Realm Therapeutics chief executive officer Alex Martin said: “The filing of the first of our two planned IND submissions in 2017 is an important milestone as Realm progresses its drug development pipeline.

"We look forward to beginning this Phase IIa study and to reviewing the subsequent data on PR022’s efficacy as a potential novel treatment for this debilitating disease."

“We look forward to beginning this Phase IIa study and to reviewing the subsequent data on PR022’s efficacy as a potential novel treatment for this debilitating disease.

See Also:

“If successful in this and future studies, our PR022 gel will provide a safe and effective alternative to topical steroids and calcineurin inhibitors for children and adults suffering from atopic dermatitis.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase IIa trial will be carried out as a randomised, double-blind, vehicle-controlled, multi-centre, parallel-group evaluation in order to assess the safety and efficacy of multiple doses of PR022 in adult patients with mild-to-moderate AD.

AD is a form of eczema that is chronic, relapsing and inflammatory and results in itchy, inflamed skin, which significantly affects a patient’s quality of life and overall healthcare system.